| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 177.148 | 344.130 | 425.176 |
| Total Income - EUR | - | - | - | - | - | - | - | 179.755 | 349.298 | 425.908 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 132.045 | 243.663 | 342.882 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | 47.710 | 105.635 | 83.026 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | 46.289 | 102.837 | 71.801 |
| Employees | - | - | - | - | - | - | - | 15 | 22 | 27 |
Check the financial reports for the company - Gidimab & Nep S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | - | - | 103.713 | 140.572 | 110.375 |
| Inventories | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | - | 87.304 | 136.317 | 108.519 |
| Cash | - | - | - | - | - | - | - | 16.409 | 4.254 | 1.856 |
| Shareholders Funds | - | - | - | - | - | - | - | 46.329 | 102.892 | 71.872 |
| Social Capital | - | - | - | - | - | - | - | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | - | 57.384 | 37.679 | 38.503 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8299 - 8299" | |||||||||
| CAEN Financial Year |
8299
|
|||||||||
Comments - Gidimab & Nep S.r.l.